Lupin gets nod to launch Doxycycline capsules from USFDA; stock rises
On Tuesday (April 9), the company, through a regulatory filing, informed investors that the US Food and Drug Administration (US FDA) had given the company approval to launch the first generic version of Oracea.
Lupin shares gained over 2 per cent in Wednesday's (April 10) trade on BSE, a day after it announced the launch of the first generic version of Oracea, Doxycycline capsules.
At around 10:01 a.m., shares of Lupin traded 1.11 per cent, or Rs 17.75, higher on the BSE at Rs 1,622.8 apiece. The market capitalisation of the company stood at Rs 73,912.97 crore at around the same time.
On Tuesday (April 9), the company, through a regulatory filing, informed investors that the US Food and Drug Administration (US FDA) had given the company approval to launch the first generic version of Oracea.
"Global pharma major Lupin Limited (Lupin) today announced the launch of the first generic version of Oracea® (Doxycycline Capsules, 40 mg) in the United States, after having received approval from the United States Food and Drug Administration (U.S. FDA)," the filing read.
Doxycycline capsules (40 mg) are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.
Doxycycline capsules had estimated annual sales of USD 128 million in the US (IQVIA MAT, February 2024).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercialises a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
It is the third-largest pharmaceutical company in the U.S. by prescriptions. The company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health areas.
Lupin share price: Past performance
In a year, shares of Lupin have given a multi-bagger return of over 144 per cent against Nifty50's rise of over 28 per cent.
Catch the latest stock market updates here. For all other news related to business, politics, tech and auto, visit Zeebiz.com.
DISCLAIMER: The views and investment tips expressed by investment experts on zeebiz.com are their own and not those of the website or its management. zeebiz.com advises users to check with certified experts before taking any investment decisions
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Gold and Silver rate today (May 14, 2024): Precious metals trade in green; yellow metal above Rs 72,000 once again, white metal near Rs 85,350
RCB vs CSK IPL 2024 Ticket Booking Online: Where and how to buy RCB vs CSK tickets online - Check IPL Match 68 ticket price, other details
SIP Returns: How Rs 3,000, 5,000, and Rs 10,000 SIPs can help you build retirement corpus of Rs 1.06 cr, Rs 1.77 cr, and Rs 3.53 cr
Women loco pilots speak about their struggle; many men have to be informed even for 'washroom break' in a moving train
Bandhan Bank Q4 FY24 Results Preview: PAT, interest income likely to grow in almost double digits; asset quality may improve
Gold and Silver rate today (May 16, 2024): Yellow metal futures subdued; white metal hits record high breaches Rs 87,000 mark
11:01 AM IST